Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-122 in the Treatment of Plaque Psoriasis
NCT02515097Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Halobetasol propionate 0.05% lotion in plaque psoriasis (2 arms), sponsored by Valeant Pharmaceuticals. Primary endpoint: Percentage of Participants With Treatment Success at 8 weeks. Started Nov 2015; status: completed.
02
Drugs
Halobetasol propionate 0.05% lotion
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02515097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02515097.